Impacto do encontro de micrometástase e células tumorais isoladas nos linfonodos sentinela no câncer de mama precoce

Autores

  • Antonio Cassio Assis Pellizzon A.C. Camargo Cancer

Palavras-chave:

Biópsia de Linfonodo Sentinela, Radioterapia, Câncer de Mama, Micrometástase

Resumo

A presença de metástases linfonodais axilares é um dos fatores prognósticos mais importantes no câncer de mama e é freqüentemente utilizada para guiar as decisões da necessidade de terapias locorregional e/ou sistêmica adicionais. A questão se a dissecção axilar (AD) pode ser omitida com segurança em pacientes com câncer de mama precoce, quando células tumorais isoladas ou micrometástases são encontradas no linfonodo sentinela, permanece um assunto controverso na literatura. Com base nas evidências atuais, a AD poderia ser omitida quando micrometástases ou CTI são encontradas. Ao tomar essa decisão, deve-se levar em conta que a presença de micrometástases e CTI são sinais de uma doença biologicamente diferente, em que a radioterapia adjuvante e o tratamento sistêmico adjuvante precisam ser considerados.

Downloads

Não há dados estatísticos.

Referências

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546-53. https://doi.org/10.1056/NEJMoa012782

Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006 May 3;98(9):599-609. https://doi.org/10.1093/jnci/djj158

Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. National Surgical Adjuvant Breast and Bowel Project) B32. Lancet Oncol. 2010 Oct;11(10):927-33. https://doi.org/10.1016/S1470-2045(10)70207-2

Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, Luini A, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer. 2001;92:1378-84.

Weaver DL. Sentinel lymph nodes and breast carcinoma: which micrometastases are clinically significant? Am J Surg Pathol. 2003 Jun;27(6):842-5.

Bundred NJ, Barnes NL, Rutgers E, Donker M. Is axillary lymph node clearance required in node-positive breast cancer? Nat Rev Clin Oncol. 2015 Jan;12(1):55-61. https://doi.org/10.1038/nrclinonc.2014.188

Nahon S, Brewer Y, Kirscher S, Chauvet B, Berger C, Serin D. Axillary lymph node and bone marrow micrometastases of breast cancer. Bull Cancer. 2001 Nov;88(11):1095-104.

Giuliano AE, Morrow M, Duggal S, Julian TB. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis. 2012 Oct;29(7):687-92. https://doi.org/10.1007/s10585-012-9515-z

Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20;23(30):7703-20. https://doi.org/10.1200/JCO.2005.08.001

de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009 Aug 13;361(7):653-63. https://doi.org/10.1056/NEJMoa0904832

Youssef MM, Cameron D, Olsen S, Ferguson D. Does axillary lymph node dissection impact survival in patients with breast cancer and isolated tumour cells or micrometastasis in sentinel node? Eur J Cancer. 2017 Apr;75:167-8. https://doi.org/10.1016/j.ejca.2017.01.016

Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol. 2013 Apr;14(4):297-

https://doi.org/10.1016/S1470-2045(13)70035-4

Galimberti V, Chifu C, Rodriguez Perez S, Veronesi P, Intra M, Botteri E, et al. Positive axillary sentinel lymph node: is axillary dissection always necessary? Breast. 2011 Oct;20(Suppl. 3):S96-8. https://doi.org/10.1016/S0960-9776(11)70303-4

Houvenaeghel G, Resbeut M, Boher JM. Sentinel node invasion: is it necessary to perform axillary lymph node dissection?Randomized trial SERC. Bull Cancer. 2014;101(4):358-63. https://doi.org/10.1684/bdc.2014.1916

Downloads

Publicado

2018-01-20

Como Citar

Pellizzon, A. C. A. (2018). Impacto do encontro de micrometástase e células tumorais isoladas nos linfonodos sentinela no câncer de mama precoce. Mastology, 28(1), 37–39. Recuperado de https://revistamastology.emnuvens.com.br/revista/article/view/539

Edição

Seção

Letters to the Editor